ASLAN Approved to Start Singapore-Taiwan Trial of Cancer Drug

ASLAN Pharma, a Singapore-based biotech focused on cancer, reports it has received approvals to conduct a clinical Phase II trial in Singapore and Taiwan of ASLAN001 (varlitinib) as a  second-line treatment for cholangiocarcinoma. Cholangiocarcinoma, the second most prevalent form of liver cancer, is an aggressive form of bile duct cancer with no approved therapy. In August, ASLAN001 was granted Orphan Drug status in the US for the disease. More details.... Share this with colleagues: // //